The American Board of Psychiatry and Neurology has reviewed the 2018 Psychopharmacology Update and has approved this program as part of a comprehensive CME program, which is mandated by the ABMS as a necessary component of maintenance of certification (MOC). The activity awards 7 AMA PRA Category 1 CreditsTM and 7 Self-Assessment Category 1 CME credits.
Overview of the 17th Annual Psychopharmacology Update
This well-established one-day CME symposium offers an outstanding opportunity for education and networking with minimal disruption to your busy schedule. At this full-day course, nationally renowned faculty will cover Optimal Psychopharmacology: From First Episode to Treatment-Resistance. You will get in-depth analysis from our expert faculty and ample time to query them on topics that will help keep your practice ahead of the curve.
Who Should Attend
The 2018 Psychopharmacology Update is a CME conference designed for child and adolescent psychiatrists, general psychiatrists, geriatric psychiatrists, pharmacists, nurse practitioners, physician assistants, nurses, psychologists, social workers, and other mental health professionals interested in treating patients with psychiatric disorders to remission with measurement-based care
At the conclusion of this activity, participants should be able to:
Identify clinician-based barriers to optimal care of anxiety disorders
Match appropriate treatment to specific anxiety disorders with the goal of achieving remission.
Outline therapeutic strategies targeting treatment-resistant anxiety disorders
Discuss appropriate practice guidelines to guide in the management of bipolar disorder in clinical practice
Use evidence-based pharmacotherapy for patients newly diagnosed with bipolar disorder
Select appropriate pharmacotherapy for patients with bipolar depression
Design appropriate treatment strategies for patients with treatment resistant bipolar disorder
Interpret emerging data regarding the etiology of depression
Select an appropriate first-line therapy for patients with major depressive disorder
List factors important in the selection of second- and third-line treatment of MDD
Develop individualized treatment plans for adjunctive therapy in patients with treatment-resistant depression.
State the challenges involved in the initial management of acute schizophrenia
Identify patients with schizophrenia for whom long-acting antipsychotic injectables are appropriate.
Initiate appropriate pharmacological and non-pharmacological interventions to treat refractory psychosis and minimize adverse effects of medications
Pharmacists global learning objectives
- Recognize that major psychiatric disorders go through different stages, from first episode to a chronic treatment-resistant stage, each of which requires customized pharmacotherapy.
- Discuss the evidence-based pharmacotherapeutic approaches for first-episode psychosis, mania, depression and anxiety, keeping in mind the higher susceptibility to adverse effects in the first episode.
- Review the psychopharmacological strategies for managing the subgroup of treatment-resistant or refractory psychiatric disorders that failed to respond adequately to the evidence-based standard of care
Continuing Medical Education
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati and Global Academy for Medical Education. The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.
Physician Credit Designation
The University of Cincinnati designates this Live Activity for a maximum of 7 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physician Assistants Credit Designation
The American Academy of Physician Assistants (AAPA) accepts AMA PRA Category 1 CreditsTM from organizations accredited by the ACCME.
Pharmacist Credit Designation
Target Audience: Pharmacists
Activity Type: Knowledge-Based
Commercial support funding provided by: Alkermes and Sunovion Pharmaceuticals Inc.
The University of Cincinnati College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Universal Program Number 0050-9999-18-030-L01-P. This program is worth 6 CEU (0.6 contact hours).
Pharmacy continuing education credit will be earned based on participation in the program verified by the completion of a registration form. Program evaluations will be distributed for all program offerings.
This activity is endorsed by Current Psychiatry.
International Credit Designation
European physicians can earn their ECMEC®s by attending live events worldwide that have been granted ECMEC®s through the UESMS-EACCME procedure, and worldwide, except in Europe, that have been certified for AMA PRA Category 1 Credits™. European physicians can also earn their ECMEC®s by completing e-learning programs from providers from all over the world except in the United States, that have been granted ECMEC®s through the UEMS-EACCME procedure and from accredited providers from the United States, that have been certified for AMA PRA Category 1 Credits™.
Additionally, the following Countries and Regions have reciprocity with the ACCME:
• Bulgarian Union of Scientific Medical Societies (Bulgaria)
• Federation of Royal Colleges of Physicians (UK)
• French National Medical Council (France)
• Italian Federation of Scientific Medical Societies (Italy)
• National CME Commission of the Italian Ministry of Health (Italy)
• Royal College of Physicians and Surgeons of Canada (Canada)
• Spanish Accreditation Council for CME (Spain)
• Bavarian Chamber of Physicians (Germany)